CSIMarket Company Name, Ticker, Suppliers, else..
 
Mesoblast Ltd  (NASDAQ: MESO)
Other Ticker:  
 
 
Price: $13.4300 $-0.42 -3.032%
Day's High: $13.78 Week Perf: -3.66 %
Day's Low: $ 13.32 30 Day Perf: -14.57 %
Volume (M): 101 52 Wk High: $ 22.00
Volume (M$): $ 1,359 52 Wk Avg: $10.11
Open: $13.67 52 Wk Low: $3.91



 Market Capitalization (Millions $) 13,258
 Shares Outstanding (Millions) 987
 Employees 162
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) 71
 Capital Exp. (TTM) (Millions $) 0

Mesoblast Ltd
Mesoblast Ltd is an Australian-based regenerative medicine company that focuses on developing and commercializing cell-based therapies. The company specializes in utilizing their proprietary technology platform to develop novel treatments for a wide range of diseases including cardiovascular conditions, orthopedic disorders, and immunologic disorders. Mesoblast's therapies are based on the use of mesenchymal precursor cells, which have the ability to differentiate into various cell types and promote tissue repair and regeneration. The company has several products in various stages of clinical development, and they collaborate with pharmaceutical partners for the commercialization of their therapies.


   Company Address: Level 38 Melbourne 3000
   Company Phone Number: 9639 6036   Stock Exchange / Ticker: NASDAQ MESO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC      0% 
AMGN   -3.25%    
BCRX   -1.94%    
BIIB   -0.4%    
EXEL   -0.46%    
GILD        3.81% 
• View Complete Report
   



Product Service News

Mesoblast Limited Launches Ryoncil in the U.S. Amidst Revenue Decline and Competitive Pressures,

Published Thu, Mar 27 2025 8:36 AM UTC

On March 26, 2025, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a recognized global leader in allogeneic cellular therapies aimed at treating inflammatory diseases, announced the launch of Ryoncil (remestemcel-L) in the United States. This momentous occasion comes after Ryoncil became the first mesenchymal stromal cell (MSC) therapy to receive approval from the U.S. Food and ...
Clinical Study

Groundbreaking Approval RYONCIL Becomes First FDA-Approved MSC Therapy for Children with Severe Inflammatory Co...

Published Thu, Dec 19 2024 12:09 AM UTC

In a groundbreaking development for the field of regenerative medicine, Mesoblast Limited has announced the FDA approval of RYONCIL (remestemcel-L), marking a significant milestone as the first-ever mesenchymal stromal cell (MSC) therapy in the United States. This approval heralds a new era in the treatment of inflammatory diseases and underscores the potential of cellular t...
Management Announcement

FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Published Wed, Dec 4 2024 11:32 PM UTC

Resurgence or Retreat? Mesoblast?s Journey Through FDA Milestones and Financial TrialsIn a tumultuous year for biotechnology firms, Mesoblast Ltd (Nasdaq...
Shares

Mesoblast Secures $50 Million Funding with FDA Nod for Ryoncil?; Builds on Previous $97 Million Capital Raise,

Published Mon, Sep 30 2024 12:55 AM UTC

New York, Sept. 29, 2024 Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines aimed at treating inflammatory diseases, has announced a pivotal new financing agreement. The biotechnology powerhouse has forged a convertible note subscription agreement with its largest shareholder, Gregory George (Investor), that allows Mesoblast to issue...
Licensing Agreement

FDA Accepts Mesoblasts Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Gra...

Published Tue, Jul 23 2024 11:54 AM UTC

Abstract:This article discusses the recent acceptance of Mesoblast s Biologics License Application (BLA) by the US Food and Drug Administration (FDA) for the use of Ryoncil in the treatment of children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). If approved, Ryoncil will be the first allogeneic off-the-shelf cellular medicine in the US and the first c...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com